Trial · NCT02206984
Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT02206984, Phase 2, Completed, Priscilla McAuliffe
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Endocrine Response in Women With Invasive Lobular Breast Cancer. Trials, record NCT02206984. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02206984
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Endocrine Response in Women With Invasive Lobular Breast Cancer
- NCT number
- NCT02206984
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 201 participants, actual
- Lead sponsor
- Priscilla McAuliffe
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen, Anastrozole, Fulvestrant
- First posted
- 2014-08-01
- Last updated
- 2026-08-07
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Log-transformed Ki67 Proliferative Index | Baseline, Day 21-27 | Ki67 expression is a routine pathologic marker that is strongly associated with cell proliferation. It is extensively used as a prognostic and predictive marker in cancer. Ki67 was calculated as a percentage of 1000 tumor cells counted in both the pre- and post-treatment specimens. The primary endpoint was change in log-transformed Ki67 at post-treatment compared to baseline. We used fixed paired differences with mean (SD) log (post/pre). |
| Secondary | Pre-treatment Ki67 Proliferative Index | Baseline | Ki67 expression is a routine pathologic marker that is strongly associated with cell proliferation. It is extensively used as a prognostic and predictive marker in cancer. Ki67 was calculated as a percentage of 1000 tumor cells counted in both the pre- and post-treatment specimens. |
| Secondary | Post-treatment Ki67 Proliferative Index | Day 21-27 | Ki67 expression is a routine pathologic marker that is strongly associated with cell proliferation. It is extensively used as a prognostic and predictive marker in cancer. Ki67 was calculated as a percentage of 1000 tumor cells counted in both the pre- and post-treatment specimens. |
| Secondary | Pre-treatment Estrogen Receptor H Score | Baseline | Estrogen receptor (ER) Histologic (H) Score is calculated as the sum of intensity of staining (0 to 3+) multiplied by the proportion (%) of cells staining positive and has a dynamic range of 0 to 300. ER H score pre-treatment was determined for each of the three treatment groups. |
| Secondary | Post-treatment Estrogen Receptor (ER) H Score | Day 21-27 | Estrogen receptor (ER) Histologic (H) Score is calculated as the sum of intensity of staining (0 to 3+) multiplied by the proportion (%) of cells staining positive and has a dynamic range of 0 to 300. ER H score was determined in each of the three post treatment groups. |
| Secondary | Pre-treatment Progesterone Receptor (PR) H Score | Baseline | Progesterone receptor (PR) Histologic (H) Score is calculated as the sum of intensity of staining (0 to 3+) multiplied by the proportion (%) of cells staining positive and has a dynamic range of 0 to 300. PR H Score was determined at baseline. |
| Secondary | Post-treatment Progesterone Receptor (PR) H Score | Day 21-27 | Progesterone receptor (PR) Histologic (H) Score is calculated as the sum of intensity of staining (0 to 3+) multiplied by the proportion (%) of cells staining positive and has a dynamic range of 0 to 300. PR H score was determined post treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33947745 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02206984
GET https://conductscience.org/api/trials/v1/NCT02206984/registered